Cargando…

CD138(-) multiple myeloma cells express high level of CHK1 which correlated to overall survival in MM patient

Multiple myeloma (MM) is a disease in which abnormal plasma cells proliferate and secrete monoclonal immunoglobulin in the bone marrow. The main characteristic of plasma cells is the expression of the cell surface antigen syndecan-1 (CD138). However, the expression of CD138 is limited to terminally...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wu, Dong, Zhang, Peihua, Li, Fangmei, Shen, Ying, Chen, Hongli, Feng, Yuandong, He, Aili, Wang, Fangxia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7746343/ https://www.ncbi.nlm.nih.gov/pubmed/33197893 http://dx.doi.org/10.18632/aging.104066

Ejemplares similares

Identification of key biomarkers associated with cell adhesion in multiple myeloma by integrated bioinformatics analysis
por: Peng, Yue, et al.
Publicado: (2020)

PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib
por: Wu, Dong, et al.
Publicado: (2021)

Development of a prognostic model for overall survival in multiple myeloma using the Connect(®) MM Patient Registry
por: Terebelo, Howard R., et al.
Publicado: (2019)

Phenotypic, Genomic and Functional Characterization Reveals No Differences between CD138(++) and CD138(low) Subpopulations in Multiple Myeloma Cell Lines
por: Paíno, Teresa, et al.
Publicado: (2014)

Variability of serum novel serum peptide biomarkers correlates with the disease states of multiple myeloma
por: Bai, Ju, et al.
Publicado: (2019)

Isolation of Human CD138(+) Microparticles from the Plasma of Patients with Multiple Myeloma()
por: Krishnan, Sabna Rajeev, et al.
Publicado: (2016)

In vivo evaluation of CD38 and CD138 as targets for nanoparticle-based drug delivery in multiple myeloma
por: Omstead, David T., et al.
Publicado: (2020)

P966: SMOLDERING MULTIPLE MYELOMA (MM) PROGRESSING TO ACTIVE MM DURING FOLLOW-UP: REDUCED BONE DISEASE AND IMPROVED PROGRESSION-FREE AND OVERALL SURVIVAL COMPARED TO DE-NOVO NEWLY DIAGNOSED MM
por: Fridberg, Gil, et al.
Publicado: (2023)

Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
por: Sun, Chuang, et al.
Publicado: (2019)

Loss of Heterozygosity in the Circulating Tumor DNA and CD138+ Bone Marrow Cells in Multiple Myeloma
por: Soloveva, Maiia, et al.
Publicado: (2023)

Correlation Between Baseline 18F-FDG PET/CT Findings and CD38- and CD138-Expressing Myeloma Cells in Bone Marrow and Clinical Parameters in Patients with Multiple Myeloma
por: Cengiz, Arzu, et al.
Publicado: (2018)

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial
por: Spencer, Andrew, et al.
Publicado: (2022)

Soluble syndecan-1 (CD138): is it useful as a prognostic factor in Korean patients with multiple myeloma?
por: Lee, Je-Jung
Publicado: (2010)

Cardiovascular Involvement of a CD138-Negative Anaplastic Myeloma: A Diagnostic Dilemma
por: Choudhuri, Jui, et al.
Publicado: (2023)

Expression analysis of multiple myeloma CD138 negative progenitor cells using single molecule microarray readout
por: Jacak, Jaroslaw, et al.
Publicado: (2013)

Multiple myeloma cells expressing low levels of CD138 have an immature phenotype and reduced sensitivity to lenalidomide
por: KAWANO, YAWARA, et al.
Publicado: (2012)

Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells
por: Kishimoto, Renata Kiyomi, et al.
Publicado: (2016)

Comment on: “Validation of interphase fluorescence in situ hybridization (iFISH) of CD138 positive cells in multiple myeloma”()
por: Zalcberg Renault, Ilana
Publicado: (2016)

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

Trends in overall survival and costs of multiple myeloma, 2000–2014
por: Fonseca, R, et al.
Publicado: (2017)

Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells
por: Jeong, Tae-Dong, et al.
Publicado: (2012)

Isolation of Circulating Plasma Cells in Multiple Myeloma Using CD138 Antibody-Based Capture in a Microfluidic Device
por: Qasaimeh, Mohammad A., et al.
Publicado: (2017)

Prognostic Nomogram for the Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Zhang, Yue, et al.
Publicado: (2019)

The independent association of mean platelet volume with overall survival in multiple myeloma
por: Zhuang, Qiang, et al.
Publicado: (2016)

miRNA-seq identification and clinical validation of CD138+ and circulating miR-25 in treatment response of multiple myeloma
por: Papadimitriou, Maria-Alexandra, et al.
Publicado: (2023)

Role of CD138, CD56, and light chain immunohistochemistry in suspected and diagnosed plasma cell myeloma: A prospective study
por: Dass, Jasmita, et al.
Publicado: (2019)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

Body Mass Index and Overall Survival of Patients with Newly Diagnosed Multiple Myeloma
por: Wang, Bei, et al.
Publicado: (2022)

A Multiepitope of XBP1, CD138 and CS1 Peptides Induces Myeloma-Specific Cytotoxic T lymphocytes in T cells of Smoldering Myeloma Patients
por: Bae, Jooeun, et al.
Publicado: (2014)

Hypoxia reduces CD138 expression and induces an immature and stem cell-like transcriptional program in myeloma cells
por: KAWANO, YAWARA, et al.
Publicado: (2013)

P882: POMALIDOMIDE, DARATUMUMAB, AND DEXAMETHASONE AFTER LENALIDOMIDE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): FINAL OVERALL SURVIVAL ANALYSIS OF THE PHASE 2 MM-014 STUDY
por: Bahlis, Nizar J, et al.
Publicado: (2023)

High expression of nucleoporin 133 mRNA in bone marrow CD138+ cells is a poor prognostic factor in multiple myeloma
por: Ibata, Soushi, et al.
Publicado: (2018)

Junctional adhesion molecule C expression specifies a CD138(low/neg) multiple myeloma cell population in mice and humans
por: Brandl, Andreas, et al.
Publicado: (2022)

Paclitaxel-Fe(3)O(4) nanoparticles inhibit growth of CD138(−) CD34(−) tumor stem-like cells in multiple myeloma-bearing mice
por: Yang, Cuiping, et al.
Publicado: (2013)

Integrative analysis of the prognostic value and immune microenvironment of mitophagy-related signature for multiple myeloma
por: Jia, Yachun, et al.
Publicado: (2023)

Syndecan-1 (CD138), Carcinomas and EMT
por: Couchman, John R.
Publicado: (2021)

Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

A novel ferroptosis-related gene signature for predicting prognosis in multiple myeloma
por: Gao, Dandan, et al.
Publicado: (2023)

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2020)

Inhibitor of Apoptosis Proteins (IAPs) as therapeutic targets in Multiple Myeloma (MM)
por: Ramakrishnan, Vijay, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_pi38hqnggc53n1n5gqcfntq101